Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tagraxofusp, Azacitidine, and Venetoclax in AML with Measurable Residual Disease
NCT07148180Phase 2Recruiting
- Start
- Feb 2026
- Primary completion
- Dec 2028
- Modality
- Immunotoxins, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of tagraxofusp in acute myeloid leukemia (AML). Started Feb 2026; status: recruiting.
02
Drugs
tagraxofusp
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07148180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07148180.